Cellebrite DICLBT
Recorded

Cellebrite DI 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration42 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome, everyone, to the Cellebrite Q3 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the call over to Andrew Kramer, Vice President of Investor Relations.

Andrew KramerVP of Investor Relations

Please go ahead. Thank you, operator, and welcome to Cellebrite's third quarter 2026 financial results call.

Andrew KramerVP of Investor Relations

I am joined here this morning by our primary speakers, Shiv Ramji, Cellebrite's CEO, and David Barter, Cellebrite's CFO. Marcus Jewell, our CRO, will join for our Q&A session. This call is being recorded, and a replay will be made available on our website shortly after the call, along with a copy of our prepared remarks. Please note that today's press release and financial statements, including GAAP to non-GAAP reconciliations, are available on the Investor Relations website at investors.cellebrite.com. In addition to the press release, we posted other materials on the quarterly results page of our IR website, including a presentation to accompany our remarks, and that is embedded in your webcast viewer.

Andrew KramerVP of Investor Relations

We also added a link to a customer video, as well as our historical financial information and supplemental data for the first three quarters of 2026, each quarter of 2025, and the full years 2024 and 2023. Additionally, unless stated otherwise, our discussion of our third quarter 2026 financial metrics, as well as the financial metrics provided in our outlook, will be done on a non-GAAP basis only, and all historical comparisons are with the comparable periods of 2025. Now, I would like to remind you that today's discussion will contain forward-looking statements, including but not limited to the company's business, operations, and financial performance. All forward-looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward-looking statements not to occur. Actual results could also differ materially from historical results and/or from forecasts.

Andrew KramerVP of Investor Relations

Some of these forward-looking statements are discussed under the heading "Risk Factors" and elsewhere in the company's annual report on Form 20-F filed with the SEC on March 3, 2026. The company does not undertake to update any forward-looking statements to reflect future events or circumstances. Slide number 3 outlines the agenda for today. With that said, I would now like to turn the call over to Shiv Ramji.

Shiv RamjiCEO

Thank you, Andy, and good morning, everyone. Cellebrite executed better in Q3 with ARR, revenue, and adjusted EBITDA all finishing above our guidance. Our ARR and revenue growth were driven by strong international performance, while our U.S. federal business continued re-accelerating. Our top-line performance, combined with prudent spending, led to strong adjusted EBITDA and free cash flow. Together with our ARR growth, that produced another strong quarter of Rule of X performance. David will walk you through the quarterly performance details and our updated outlook. During the quarter, we made important strategic and operational progress. From a strategic perspective, I am particularly excited about the direction of our product team and what we will be releasing to customers. From a go-to-market perspective, I am proud of how our team responded after Q2 to deliver a much-improved Q3.

Shiv RamjiCEO

Before diving and sharing more details, I would like to cover a few highlights from the quarter. Q3 ARR growth reflects notable wallet share expansion within strategic customers who are spending more with us and across a broader range of offerings. To bring that to life, we published a customer video with our quarterly materials. It shows how Mississippi's Department of Public Safety uses Inseyets, Guardian, and Pathfinder together and helps illustrate our mission as an AI-powered public safety company that makes the world a safer place. We encourage you to watch it. In terms of our Q3 performance, let's begin with U.S. federal, where growth has steadily increased over three quarters. This trend reflects our continued success in expanding the scope of our customer relationships. This was best exemplified in Q3 when two of our largest U.S. federal customers each increased spending by over 20% year over year.

Shiv RamjiCEO

We closed our first large FedRAMP deal for Guardian in Q3, which is also the single largest Guardian win to date. In addition to this milestone, four other U.S. agencies began using Guardian this quarter. Outside the U.S., EMEA grew 22% and Asia Pacific grew 31%, with solid expansion across law enforcement and defense and intelligence. We had a great win at a U.K. regional police agency where on-prem and kiosk forensics plus Guardian created a scalable Cellebrite ecosystem and displaced a competitor. In defense and intelligence, which continues to grow in the mid-20s, demand for point-of-collection intelligence is rising. In Q3, a major Asia-Pacific military unit expanded its spend with us by nearly 60% on orders for field-ready phone and drone data collection solutions. Other key metrics also trended positively.

Shiv RamjiCEO

Inseyets conversions increased meaningfully from nearly 65% of the install base at the end of Q2 to 75% at the end of Q3. Advanced Unlocks also made good progress, doubling customers over Q2 with very strong sequential ARR growth. Just as notable, Genesis gained meaningful traction in its first full quarter. Genesis finished Q3 with $2 million in ARR as we continued to see strong adoption by customers. Perhaps most telling, Genesis was not in our customers' annual budgets this year. The deals we have won and those we expect to close in Q4 reflect customers so convinced of Genesis' value that they reprioritized spending to fund it. Customers continue to share the powerful impact that Genesis is making. Genesis surfaces evidence in minutes that would otherwise take hours or days of manual review.

Shiv RamjiCEO

Its capabilities extend beyond mobile forensics, helping investigators synthesize video, audio calls, financial records, and other evidentiary artifacts to surface leads. A Florida detective recently shared that Genesis helped analysts search two years of jail calls and in just 15 minutes, surface a murder confession and plans for a cover-up. For this detective, Genesis was the difference between evidence that exists and evidence that is found. Looking ahead, we plan to introduce an on-premise AI version of Genesis before year-end for customers doing highly sensitive work in air-gapped environments. We have already lined up early design partners in the D&I segment to help build out these capabilities, extending our reach beyond tactical collection into strategic and national intelligence missions. We also continue to invest in innovation and made important progress.

Shiv RamjiCEO

In September, we announced that Chris Wade, our CTO, had assumed leadership of Cellebrite Labs, which conducts a critical mobile research used in our Inseyets product. This team is now benefiting from additional infrastructure, AI resources, research tools, and talent to keep pace with the rapidly evolving device landscape. As we have shared, AI is disruptive in mobile security. It helps phone manufacturers close vulnerabilities faster, but AI-written code also creates more flaws. We use AI to find those flaws and bring updated capabilities to market faster. Labs plans to deliver updated capabilities and next-generation hardware across Android, Apple iOS, feature phones, and alternative operating systems before year-end. We expect this new wave of innovation will resonate with customers and clearly distance our offering from competition. In August, we launched C-Tek, our portable tactical data collection kit for defense and intelligence agencies, and early customer interest is encouraging.

Shiv RamjiCEO

On the corporate front, the most significant development was our September announcement that we plan to redomicile in the United States. Redomiciling is a strategic evolution that we believe better positions us to drive growth in our largest market and beyond. More specifically, we expect it to eliminate sales friction tied to our foreign entity status and make us eligible for major U.S. stock indices, broadening our reach to passive capital and actively managed funds. Initial customer feedback has been very positive, which bodes well after a strong Q3 in U.S. federal. Nevertheless, we were disappointed by limited new sales and higher-than-expected churn for Corellium. We continue to work with CFIUS on a final NSA for Corellium. We are also building out our leadership team.

Shiv RamjiCEO

Last week, we announced the appointment of Rogerio Rizzi as Executive Vice President of Corporate Strategy and Development, bringing substantial experience in AI, technology, and M&A to our company. In addition, we are making good progress on our search for a new leader of our product and technology organization, which we initiated when I became CEO. Today, Cellebrite moves forward with a strong foundation that was built by delivering market-leading digital forensic solutions for a specialized, highly technical user community. In recent years, we have broadened our offerings to address the workflow, collaboration, and analytic needs of investigators, analysts, field agents, command staff, and prosecutors. From proprietary machine learning models to new agentic capabilities, AI is infused into every Cellebrite solution, maximizing the impact of our solutions across different customer segments and user constituencies.

Shiv RamjiCEO

In 2027, Genesis will evolve from a purpose-built agentic AI product into an AI-native platform that will collect digital evidence from devices, cloud services, and other sources, securely share and analyze vast volumes of relevant artifacts, facilitate mission-critical workflows, and rapidly deliver trusted, court-ready insight and decisive operational intelligence. We believe Genesis will become the standard for how our customers conduct investigations and advance intelligence-led operations. There are three primary things I'd like to emphasize. First, the roadmap. Over the next 12 months, we will bring proven market-leading solutions onto our Genesis platform and deliver it in the environment that best suits our customers, from air-gapped and on-premise, with an option for forward-deployed engineers, to cloud and hybrid.

Shiv RamjiCEO

Underpinning that flexibility will be innovations in collecting digital evidence, managing investigative workflows, and analyzing an ever-expanding range of artifacts, anchored by a new unified evidence format that is optimized for Cellebrite's platform and ecosystem. Executing on this roadmap involves reshaping how we build products. We're moving from a feature-focused structure to one where AI agents work alongside our engineers, product managers, and forensic experts to take ideas from discovery to validated release faster, without sacrificing quality or security. This is enabling us to integrate agents and capabilities on top of our forensic foundation with the provenance, verification, and human oversight that support our customers' chain of custody requirements, legal frameworks, and investigative protocols. Second, hardware. Customers need faster access to more devices and faster insight from them.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day